Holen Sie sich die Stockscreener-App
2.77
0.73%
0.02
Okyo Pharma Limited Aktie (OKYO) Neueste Nachrichten
Is OKYO Pharma Limited a good long term investmentPhenomenal trading returns - Autocar Professional
OKYO Pharma Limited Stock Analysis and ForecastSuperior portfolio returns - jammulinksnews.com
What analysts say about OKYO Pharma Limited stockRapid-fire capital growth - jammulinksnews.com
What drives OKYO Pharma Limited stock priceHigh-profit capital plays - jammulinksnews.com
OKYO Pharma Secures $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - VisionMonday.com
OKYO Pharma CEO details positive results from Phase 2 urcosimod trialICYMI - Proactive financial news
OKYO Pharma Secures $1.9M Non-Dilutive Funding to Advance Urcosimod Development - AInvest
OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain - Ophthalmology Times
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding - GlobeNewswire
OKYO Pharma receives $1.9 million non-dilutive funding for lead drug development - Investing.com Nigeria
Small cap wrap: Digi Power X, American Resources, OKYO Pharma, Lisata Therapeutics... - Proactive financial news
OKYO Slides Despite Fresh R&D Funding - Baystreet.ca
OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug - Investing.com Canada
Okyo Pharma Obtains $1.9 Million Non-Dilutive Funding - MarketScreener
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development - TipRanks
OKYO Pharma bolsters ocular pain program with $1.9M non-dilutive financing - Proactive financial news
OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug By Investing.com - Investing.com South Africa
OKYO’s Market Whiplash: 86.16% YTD Rise, -1.66% Plunge in 30 Days - investchronicle.com
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - MarketScreener
OKYO Secures $1.9M to Fast-Track Revolutionary Eye Pain Drug with No Current FDA Treatment - Stock Titan
OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data By Investing.com - Investing.com South Africa
OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data - Investing.com Australia
OKYO Pharma Limited Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - MarketScreener
OKYO Pharma Receives Positive Buy Rating from H.C. Wainwright - AInvest
Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation - TipRanks
OKYO posts trial data for lead drug in eye pain (OKYO:NASDAQ) - Seeking Alpha
OKYO Pharma reports positive Phase 2 data in treating Neuropathic Corneal Pain - Proactive financial news
Small cap wrap: OKYO Pharma, North Bay Resources, Nevis Brands, Nextech3D.ai... - Proactive financial news
OKYO Pharma Says Phase 2 Study of Urcosimod Showed 'Marked Reduction' in Neuropathic Corneal Pain Scores - MarketScreener
OKYO Pharma stock surges after positive Phase 2 results for eye pain drug - Investing.com Australia
OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain - TipRanks
OKYO Pharma reports positive top-line results from Phase 2 urcosimod trial - Investing.com Nigeria
OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain - Proactive financial news
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewswire
How FIGS Inc. stock performs during market volatilityFree Step-by-Step Investment Guide - Newser
What makes OKYO Pharma Limited stock price move sharplyConsistent Growth Alert - Newser
How ArrowMark Financial Corp. stock performs during market volatilityFree Stock Market Courses - Newser
4.79%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):